{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T02:23:00Z","timestamp":1776219780357,"version":"3.50.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C60293\/A28497"],"award-info":[{"award-number":["C60293\/A28497"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain, Behavior, & Immunity - Health"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.bbih.2024.100865","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T20:58:09Z","timestamp":1726779489000},"page":"100865","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Characterising how a single bout of exercise in people with myeloma affects clonal plasma cell and immune effector cell frequency in blood, and daratumumab efficacy in vitro"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3734-0792","authenticated-orcid":false,"given":"Harrison D.","family":"Collier-Bain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annabelle","family":"Emery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frankie F.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam J.","family":"Causer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Eddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoji","family":"Leach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Graby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Augustine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josephine","family":"Crowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James E.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9989-6158","authenticated-orcid":false,"given":"John P.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbih.2024.100865_bib1","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1182\/blood-2021-147897","article-title":"Daratumumab (DARA) with bortezomib, thalidomide, and dexamethasone (VTd) in transplant-eligible patients (Pts) with newly diagnosed multiple myeloma (NDMM): analysis of minimal residual disease (MRD) negativity in cassiopeia Part 1 and Part 2","volume":"138","author":"Avet Loiseau","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bbih.2024.100865_bib2","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1152\/jappl.1986.60.6.2020","article-title":"A new method for detecting anaerobic threshold by gas exchange","volume":"121","author":"Beaver","year":"1986","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.bbih.2024.100865_bib3","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bbi.2013.10.030","article-title":"Acute exercise preferentially redeploys NK-cells with a highly-differentiated phenotype and augments cytotoxicity against lymphoma and multiple myeloma target cells","volume":"39","author":"Bigley","year":"2014","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbih.2024.100865_bib4","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1249\/00005768-198205000-00012","article-title":"Psychophysical bases of perceived exertion","volume":"14","author":"Borg","year":"1982","journal-title":"Med. Sci. Sports Exerc."},{"key":"10.1016\/j.bbih.2024.100865_bib5","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3389\/fimmu.2018.00648","article-title":"Debunking the myth of exercise-induced immune suppression: redefining the impact of exercise on immunological health across the lifespan","volume":"9","author":"Campbell","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbih.2024.100865_bib6","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.bbi.2009.02.011","article-title":"Acute exercise mobilises CD8+ T lymphocytes exhibiting an effector-memory phenotype","volume":"23","author":"Campbell","year":"2009","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbih.2024.100865_bib7","year":"2014"},{"key":"10.1016\/j.bbih.2024.100865_bib8","unstructured":"Cancer Research UK, 2017. In: Myeloma Statistics. https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/myeloma#heading-Zero. (Accessed 23 April 2020)."},{"key":"10.1016\/j.bbih.2024.100865_bib9","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","article-title":"Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma","volume":"1","author":"Casneuf","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.bbih.2024.100865_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1244090","article-title":"Harnessing the immunomodulatory effects of exercise to enhance the efficacy of monoclonal antibody therapies against B-cell haematological cancers: a narrative review","volume":"13","author":"Collier-Bain","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbih.2024.100865_bib11","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.bbi.2024.03.023","article-title":"A single bout of vigorous intensity exercise enhances the efficacy of rituximab against human chronic lymphocytic leukaemia B-cells ex vivo","volume":"118","author":"Collier-Bain","year":"2024","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbih.2024.100865_bib12","article-title":"Downhill running does not alter blood C1q availability or complement-dependent cytotoxicity of therapeutic monoclonal antibodies against haematological cancer cell lines in vitro","author":"Collier-Bain","year":"2024","journal-title":"Manuscript under review"},{"key":"10.1016\/j.bbih.2024.100865_bib13","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.3324\/haematol.2015.139667","article-title":"Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance","volume":"101","author":"de Haart","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.bbih.2024.100865_bib14","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbih.2024.100865_bib15","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.psyneuen.2012.05.008","article-title":"Stress-induced redistribution of immune cells--from barracks to boulevards to battlefields: a tale of three hormones--Curt Richter Award winner","volume":"37","author":"Dhabhar","year":"2012","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.bbih.2024.100865_bib16","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.bbih.2024.100865_bib17","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1182\/blood-2012-08-448548","article-title":"Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans","volume":"121","author":"Gorgun","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bbih.2024.100865_bib18","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/leu.2016.205","article-title":"Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression","volume":"31","author":"Gonsalves","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.bbih.2024.100865_bib19","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.bbih.2024.100865_bib20","year":"2019"},{"key":"10.1016\/j.bbih.2024.100865_bib21","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.bbi.2007.08.008","article-title":"Exercise-induced redistribution of T lymphocytes is regulated by adrenergic mechanisms","volume":"22","author":"Kr\u00fcger","year":"2008","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbih.2024.100865_bib22","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nri1203","article-title":"Plasma-cell homing","volume":"3","author":"Kunkel","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbih.2024.100865_bib23","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbih.2024.100865_bib24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.bbih.2024.100865_bib25","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3389\/fpsyg.2013.00863","article-title":"Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs","volume":"4","author":"Lakens","year":"2013","journal-title":"Front. Psychol."},{"key":"10.1016\/j.bbih.2024.100865_bib26","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbih.2024.100865_bib27","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbih.2024.100865_bib28","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bbih.2024.100865_bib29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.bbih.2024.100865_bib30","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/leu.2015.123","article-title":"Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab","volume":"29","author":"Nijhof","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.bbih.2024.100865_bib31","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the eastern cooperative Oncology group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.bbih.2024.100865_bib32","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2008-05-159624","article-title":"Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation","volume":"112","author":"Paiva","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbih.2024.100865_bib33","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.cmet.2016.01.011","article-title":"Voluntary running suppresses tumor growth through epinephrine- and IL-6-dependent NK cell mobilization and redistribution","volume":"23","author":"Pedersen","year":"2016","journal-title":"Cell Metabol."},{"key":"10.1016\/j.bbih.2024.100865_bib34","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbih.2024.100865_bib35","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1084\/jem.170.2.481","article-title":"Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions","volume":"170","author":"Ravetch","year":"1989","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbih.2024.100865_bib36","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-018-0153-9","article-title":"Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)","volume":"8","author":"Sanoja-Flores","year":"2018","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bbih.2024.100865_bib37","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1182\/blood.2019002610","article-title":"Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy","volume":"134","author":"SanojaFlores","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bbih.2024.100865_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-009576","article-title":"Multiple myeloma and physical activity: a scoping review","volume":"5","author":"Smith","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.bbih.2024.100865_bib39","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1158\/1078-0432.CCR-17-0691","article-title":"Nitric oxide production by myeloid-derived suppressor cells plays a role in impairing Fc receptor\u2013mediated natural killer cell function","volume":"24","author":"Stiff","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbih.2024.100865_bib40","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1158\/1078-0432.CCR-22-1594","article-title":"Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma","volume":"28","author":"Termini","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbih.2024.100865_bib41","first-page":"338","article-title":"Revision of the physical activity readiness Questionnaire (PAR-Q)","volume":"17","author":"Thomas","year":"1992","journal-title":"Can. J. Sport Sci."},{"key":"10.1016\/j.bbih.2024.100865_bib42","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.physbeh.2016.06.023","article-title":"Exercise-induced B cell mobilisation: preliminary evidence for an influx of immature cells into the bloodstream","volume":"164","author":"Turner","year":"2016","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.bbih.2024.100865_bib43","doi-asserted-by":"crossref","first-page":"E881","DOI":"10.1097\/HS9.0000000000000881","article-title":"NK cell phenotype is associated with response and resistance to daratumumab in relapsed\/refractory multiple myeloma","volume":"7","author":"Verkleij","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.bbih.2024.100865_bib44","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1189\/jlb.0912461","article-title":"Blood CD33(+)HLA-DR(\u2212) myeloid-derived suppressor cells are increased with age and a history of cancer","volume":"93","author":"Verschoor","year":"2013","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.bbih.2024.100865_bib45","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1158\/1078-0432.CCR-17-3117","article-title":"Fratricide of NK cells in daratumumab therapy for multiple myeloma overcome by ex vivo\u2013expanded autologous NK cells","volume":"24","author":"Wang","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbih.2024.100865_bib46","doi-asserted-by":"crossref","DOI":"10.1038\/srep34310","article-title":"CD16 is indispensable for antibodydependent cellular cytotoxicity by human monocytes","volume":"6","author":"Yeap","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbih.2024.100865_bib47","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1080\/19420862.2019.1601985","article-title":"Important roles of CD32 in promoting suppression of IL-4 induced immune responses by a novel anti-IL-4R\u03b1 therapeutic antibody","volume":"11","author":"Zhao","year":"2019","journal-title":"mAbs"}],"container-title":["Brain, Behavior, & Immunity - Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666354624001431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666354624001431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T02:15:45Z","timestamp":1737425745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666354624001431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":47,"alternative-id":["S2666354624001431"],"URL":"https:\/\/doi.org\/10.1016\/j.bbih.2024.100865","relation":{},"ISSN":["2666-3546"],"issn-type":[{"value":"2666-3546","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterising how a single bout of exercise in people with myeloma affects clonal plasma cell and immune effector cell frequency in blood, and daratumumab efficacy in vitro","name":"articletitle","label":"Article Title"},{"value":"Brain, Behavior, & Immunity - Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbih.2024.100865","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100865"}}